Hemogenyx Pharmaceuticals PLC Development of ApbHC (1073D)
24 June 2019 - 4:00PM
UK Regulatory
TIDMHEMO
RNS Number : 1073D
Hemogenyx Pharmaceuticals PLC
24 June 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Development of ApbHC, a Novel Type of Humanized Mouse
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that its
wholly owned subsidiary Immugenyx, LLC ("Immugenyx") has developed
an Advanced peripheral blood Hematopoietic Chimera ("ApbHC"), a
novel type of humanized mouse that presents several advantages over
other mouse models. Immugenyx was established by the Company to
develop and commercialise the Company's Advanced Hematopoietic
Chimeras (AHC) or humanized mice and the new ApbHC represents a
significant further development in that direction.
As with AHC, the Company believes that the ApbHC will be of
considerable interest to other drug developers and initial interest
shown is promising.
The ApbHC was initially developed as a research and development
tool for the investigation of mature blood cell populations such as
human T-cells, B-cells and antibody-producing plasma cells. The
major advantage of the ApbHC compared to other humanized mouse
models known to the Directors is the absence of Graft versus Host
Disease, a disease that complicates and often renders impossible
the efficient use of peripheral blood mononuclear cells in
transplanted mice. Hemogenyx has demonstrated that the ApbHC can
potentially be used for testing multi-specific antibodies,
including its own bi-specific CDX antibody for the elimination of
acute myeloid leukemia (AML) and the conditioning of patients for
bone marrow transplantation. ApbHC may also be used for the
development and testing of new cell therapies involving immune cell
reprogramming, such as CAR-T. Immugenyx has further demonstrated
that the ApbHC can potentially be used for the modeling of
autoimmune diseases, such as Systemic Lupus Erythematosus (aka
Lupus), with a goal of developing fundamentally new treatments for
those diseases. The Directors also believe that the ApbHC could
potentially be used as a tool for the rapid development and/or
isolation of human antibodies against unknown human-specific
pathogens (biodefense applications).
Vladislav Sandler, Chief Executive Officer, commented, "We are
excited by the potential of the ApbHC, a new generation of our
humanized mice. The ApbHC has allowed us to rapidly obtain in vivo
data on the efficacy of our CDX antibodies against AML. We are
actively developing and expanding the potential use of the ApbHC
for disease modeling, the development of new therapeutics, and
biodefense applications. Our ApbHC has also generated significant
interest from third parties who also see its potential for disease
modeling and drug development."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Sir Marc Feldmann, Executive Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its wholly-owned
US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located
at its state-of-the-art research facility in New York City and a
wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL,
located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFJMJTMBJTBJL
(END) Dow Jones Newswires
June 24, 2019 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024